Astria stockholders vote to approve acquisition by BioCryst

Astria Therapeutics, Inc. (ATXS) announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals (BCRX). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.